[
  {
    "ts": null,
    "headline": "Can BMYs Neuroscience Portfolio Help to Diversify Its Business?",
    "summary": "Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.",
    "url": "https://finnhub.io/api/news?id=ae4880b418ba9bc7428553f78b9bb77a046643587af3434b8468afc8129c0deb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759935360,
      "headline": "Can BMYs Neuroscience Portfolio Help to Diversify Its Business?",
      "id": 137012865,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.",
      "url": "https://finnhub.io/api/news?id=ae4880b418ba9bc7428553f78b9bb77a046643587af3434b8468afc8129c0deb"
    }
  },
  {
    "ts": null,
    "headline": "Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=85e9e4666e16ecd85cb3c78b7c77165c3984bcfc04e9a8e8bbfa80c7a44a7b83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759930802,
      "headline": "Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term",
      "id": 137013075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=85e9e4666e16ecd85cb3c78b7c77165c3984bcfc04e9a8e8bbfa80c7a44a7b83"
    }
  },
  {
    "ts": null,
    "headline": "Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings",
    "summary": "Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.",
    "url": "https://finnhub.io/api/news?id=4222835e405c672e97b2d5ef9e8bc676ddc39cdc39fdafa5fb4cb7dc23c73cd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759927800,
      "headline": "Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings",
      "id": 137010956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.",
      "url": "https://finnhub.io/api/news?id=4222835e405c672e97b2d5ef9e8bc676ddc39cdc39fdafa5fb4cb7dc23c73cd8"
    }
  }
]